Bookmarks
The development of risk-stratified blood-test monitoring strategies for common inflammatory conditions treated with immune suppressing drugs
Safe People
Organisation name
University of Nottingham
Organisation sector
Academic Institute
Applicant name(s)
Abhishek Abhishek - Chief Investigator - University of NottinghamGeorgina Nakafero - Corresponding Applicant - University of NottinghamChristian Mallen - Collaborator - Keele UniversityDanielle van der Windt - Collaborator - Keele UniversityMatthew Grainge - Collaborator - University of NottinghamRichard Riley - Collaborator - Keele UniversityTimothy Card - Collaborator - University of Nottingham
Safe Projects
Project ID
CPRD686
Lay summary
Medicines such as methotrexate suppress the immune-system and are used to treat conditions like rheumatoid arthritis (RA) that result from an overactive immune-system. Patients treated with these medicines may develop side-effects such as blood, liver or kidney damage, and, fortnightly to monthly blood tests are performed to detect them early, before any permanent damage can occur. However, these side-effects become less common after the first few months of treatment. Nevertheless, monitoring with periodic blood tests is continued indefinitely for all patients treated with these medicines. The benefit from such long-term monitoring is not known, and, whether all patients should undergo regular blood-tests indefinitely needs to be determined.
Technical summary
Background: The optimal monitoring strategy for adults with common inflammatory conditions treated with long-term immune-suppressing drugs is not known.
Latest approval date
16/03/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
Safe Setting
Access type
Release